The company is the subject of a securities fraud lawsuit alleging it made false and misleading statements about its clinical trial design and concealed adverse facts, resulting in investor losses when the truth was revealed.
Company faces securities litigation alleging executives concealed material information about trial design flaws and placebo risks. Phase 3 trial failure resulted in 80% stock decline and Nasdaq delisting risk. Allegations of deliberate investor deception regarding trial efficacy expectations.
Company is subject to securities class action lawsuit alleging false and misleading statements regarding Phase 3 PROSERA study design and concealment of material adverse facts, resulting in investor damages.
Company faces securities litigation for allegedly misleading investors about trial design and efficacy. Phase 3 trial failure resulted in 80% stock decline, Nasdaq delisting risk (share price below $1 minimum), and significant investor losses. Management allegedly knew of trial design issues but assured investors of success.
The company is accused of providing false and misleading statements about its Phase 3 PROSERA study while concealing material adverse facts about study design, resulting in a class action lawsuit and investor losses due to artificially inflated stock prices.
Company is defendant in securities class action lawsuit alleging false and misleading statements regarding Phase 3 PROSERA study design and concealment of material adverse facts, resulting in investor damages.
The company is accused of making materially false and misleading statements about clinical trial results, concealing adverse facts about study design, and causing investors to purchase shares at artificially inflated prices. These allegations of securities fraud and investor deception warrant a negative sentiment rating.
Company is subject to securities class action lawsuit alleging defendants provided false and misleading statements regarding Phase 3 PROSERA study design, particularly concerning placebo response controls at Latin American testing sites, resulting in investor damages.
Company faces class action lawsuit for alleged securities fraud following a significant stock price collapse of 80.13% due to failed Phase 3 clinical trial results that missed primary endpoints, raising concerns about prior disclosures and business practices.
The company is the subject of a securities class action lawsuit alleging that defendants provided false and misleading statements about their Phase 3 PROSERA study design while concealing material adverse facts. This resulted in investor damages when the true details became public.
The company faces a securities fraud lawsuit following an 80% stock price collapse due to a failed Phase 3 clinical trial. Allegations include materially misleading statements about trial design and concealment of enrollment risks that compromised study outcomes, representing significant legal and financial liability.
Alleged failure to disclose that Phase 3 clinical trial failed to meet primary endpoint due to patient selection issues and placebo performance.
The company is the defendant in a class action lawsuit alleging material misrepresentations and omissions regarding clinical trial design, which caused investors to purchase securities at artificially inflated prices. This represents significant legal and reputational risk.
The company is the subject of a securities class action lawsuit alleging that defendants provided false and misleading statements regarding study design and concealed material adverse facts, resulting in investor damages when the truth was revealed.
The company is the subject of a securities class action lawsuit alleging that defendants provided false and misleading statements while concealing material adverse facts about a clinical study design, resulting in investor damages when the truth was revealed.
The company is the subject of a securities class action lawsuit alleging that defendants provided false and misleading statements while concealing material adverse facts about their Phase 3 clinical study design, resulting in investor damages.
Company faces securities class action lawsuit alleging fraudulent misrepresentation regarding trial design and patient recruitment. Phase 3 trial failure resulted in 80% stock decline and Nasdaq delisting risk due to failure to maintain minimum bid price.
The company is the subject of a securities class action lawsuit alleging false and misleading statements about clinical trial design and concealment of material adverse facts, which resulted in investor damages when the truth was revealed.
Company is accused of providing false and misleading statements about clinical study design and concealing material adverse facts, resulting in investor damages when the truth was revealed.
The company is accused of making materially false and misleading statements regarding its Phase 3 PROSERA study. The study failed to meet its primary endpoint due to undisclosed enrollment of heavily-treated, lower-risk patients at Latin American sites. The stock experienced an 80.3% price decline following the disclosure, and shareholders are pursuing legal action to recover losses.
Company is defendant in class action lawsuit alleging materially false and misleading statements regarding Phase 3 clinical study results, indicating potential fraud and significant shareholder losses.
The company is accused of providing false and misleading statements about its Phase 3 PROSERA study while concealing material adverse facts about study design. The trial failed to meet its primary endpoint, resulting in an 80% stock price collapse and triggering a securities class action lawsuit.
Company's Phase 3 PROSERA trial failed to meet primary endpoint, resulting in an 80.14% stock price decline. Securities fraud investigation initiated by major law firm indicates serious concerns about potential misconduct or misrepresentation.
Articles that tag GOSS but are mainly about other companies.
Company secured $250 million in private placement financing for seralutinib development in PAH and PH-ILD, with planned NDA submission in September 2026, indicating strong investor confidence and advancement toward market entry.
Announced topline results for PROSERA Phase III study of seralutinib in PAH patients, advancing lead candidate toward potential commercialization
Company is subject to securities class action lawsuit (details partially provided in article), indicating alleged misconduct or misstatements affecting investor interests.
Company is subject to a securities class action lawsuit (details partially provided in article), indicating alleged securities violations.
Company is subject to a securities class action lawsuit, though specific allegations are not detailed in the provided excerpt. The mere existence of such litigation indicates investor concerns.
Company is subject to a securities class action lawsuit filed by Rosen Law Firm, indicating alleged securities violations.
Company is subject to a securities class action lawsuit filed by Rosen Law Firm, though specific allegations are not detailed in the provided excerpt.
Mentioned as subject of a separate class action lawsuit for alleged securities fraud violations, indicating similar investor harm concerns.
Company allegedly concealed clinical execution failures related to the PROSERA trial, resulting in a securities fraud lawsuit for misrepresentations about trial progress.
Gossamer Bio's Seralutinib is highlighted as an inhaled inhibitor in development for PAH and PH-ILD, representing advanced pipeline innovation in the expanding ILD treatment landscape.
Phase 3 PROSERA trial of seralutinib for PAH missed the prespecified statistical threshold (p=0.0320 vs. alpha=0.0257), requiring FDA meeting to discuss path forward despite showing modest clinical benefit.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
